Ala. Admin. Code r. 420-4-1- AIII
| Bacillus anthracis |
| Botulinum neurotoxin-producing species of Clostridium |
| Brucella abortus |
| Brucella melitensis |
| Brucella suis |
| Burkholderia mallei |
| Burkholderia pseudomallei |
| Campylobacter spp. |
| Candida auris |
| Carbapenem-resistant Enterobacteriaceae (CRE) |
| Carbapenem-resistant Pseudomonas aeruginosa (CRPA) |
| Carbapenem-resistant Acinetobacter baumannii (CRAB) |
| Coxiella burnetii |
| Cryptosporidium spp. |
| E. coli, shiga-toxin producing |
| Ebola |
| Francisella tularensis |
| Haemophilus influenzae from a normally sterile site |
| Legionella spp. from a lower respiratory sample |
| Listeria monocytogenes |
| Mycobacterium tuberculosis |
| Naegleria fowleri |
| Neisseria meningitidis from a normally sterile site |
| Novel Coronaviruses |
| Novel Influenza |
| Salmonella serotype Typhi |
| Salmonella spp., non-Typhoidal |
| Shigella spp. |
| Streptococcus pneumoniae from a normally sterile site * |
| Variola (Smallpox virus) |
| Vibrio spp. |
| Yersinia pestis |
| * Submit all CSF isolates. Other isolates from normally sterile sites (e.g., blood, middle ear fluid, joint fluid, or peritoneal fluid) must be non-susceptible to any relevant antibiotics according to current Clinical Laboratory Standards Institute M100 guidance. |
Author: Sherri L. Davidson, Ph.D, M.P.H., Sharon Massingale, Ph.D, HCLD/CC(ABB)
Statutory Authority: Code of Ala. 1975, §22-11A-13.
History: New Rule: Published February 29, 2024; effective April 14, 2024.